AcuCort AB is a Sweden-based pharmaceutical company. The company develops oral films ISICORT, which involve chemical substance glucocorticoid dexamethasone that is used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. AcuCort AB operates mostly in Nordic countries.

Employees

Sector

Drug Retailers

Calendar

11-05 Earnings release - Q3 2026

More about the company

End-of-day quote SPOTLIGHT STOCK MARKET AB 30/09/2026			5-day change	1st Jan Change
0.4980 ^SEK	+0.20%		-.--%	-17.00%

10-05	Acucort: 'Regulatory risk has declined significantly' - CEO	FW
10-05	AcuCort to Raise Equity in Bid to Secure US Regulatory Approval for Zeqmelit	MT

Market Cap	117M 11.76M 10.5M 9.7M 8.79M 16.45M 1.12B 16.72M 46.22M 585M 44.14M 43.2M 1.84B	P/E 2024	-3.61x	P/E 2025	-5x
Enterprise Value	89.74M 9.04M 8.07M 7.46M 6.76M 12.64M 858M 12.85M 35.53M 450M 33.93M 33.2M 1.42B	EV / Sales 2024	129,716,884x	EV / Sales 2025	165,436,272x
Free-Float	67.7%	Yield 2024 *	-	Yield 2025	-

10-05	Acucort: 'Regulatory risk has declined significantly' - CEO	FW
10-05	AcuCort to Raise Equity in Bid to Secure US Regulatory Approval for Zeqmelit	MT
10-05	Acucort seeks to raise SEK 70m in rights issue	FW
09-28	Acucort highlights higher willingness to pay for oral film	FW
09-16	AcuCort Secures Funds from Swedish Regional Body for US Expansion	MT
09-16	Acucort receives 150,000 kronor in support from Region Skåne for US expansion	FW
09-16	AcuCort AB Receives Funding From Region Skåne To Support US Expansion	CI
09-08	AcuCort AB Registers Zeqmelit as Trade Mark in Ukraine	CI
09-07	Acucort wins trademark protection for Zeqmelit in Ukraine	FW
09-01	Acucort's warrant program was fully subscribed	FW
08-26	Acucort study published in scientific journal	FW
08-24	Acucort appoints Carl Frisk as Strategic Alliance Manager	FW
08-19	Acucort lifts revenue in Q2	FW

10-14	AcuCort : Capital Markets Day – watch the presentation	PU
10-06	AcuCort's CEO Jonas Jönmark to take part in live broadcast on rights issue and US expansion	AQ
10-06	AcuCort invites investors to Capital Markets Day on 13 October	AQ
10-05	AcuCort AB resolves on a rights issue of units of initially approximately SEK 70.3 million to finance continued efforts towards FDA approval and accelerate commercialization, and raises a bridge loan	AQ
09-28	AcuCort publishes September 2026 newsletter	AQ

AcuCort AB Stock

Stocks

ACUC

SE0009695927

Drug Retailers

Valuation: AcuCort AB

Chart: AcuCort AB

Latest news: AcuCort AB

Press Releases: AcuCort AB

Quotes and Performance

Price Extremes

Managers and Directors: AcuCort AB

Other Drug Retailers

Financials

Company Profile

1 day	+0.20%
1 month	+1.01%
3 months	-20.95%
6 months	-37.28%
Current year	-17.00%

1 month	0.48	0.52
Current year	0.4	0.95
1 year	0.4	0.95
3 years	0.33	1.26
5 years	0.33	3.4
10 years	0.33	9.5

Manager	Title	Age	Since
Jonas Jonas Jönmark CEO	Chief Executive Officer	55	09/08/2020
Anna Cherouvrier Hansson PRN	Corporate Officer/Principal	53	14/10/2025

Director	Title	Age	Since
Anna Maria Albertina Eriksrud BRD	Director/Board Member	68	08/02/2017
Ebba Cecilia Fåhraeus CHM	Chairman	63	01/01/2018
Göran Tornling BRD	Director/Board Member	79	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACUCORT AB	+0.20%	-.--%	-24.32%	+16.08%	11.76M
JD HEALTH INTERNATIONAL INC.	-1.00%	-2.49%	-39.84%	+10.43%	15.29B
RAIA DROGASIL S.A.	+10.52%	-1.36%	+5.65%	-21.56%	7.04B
MATSUKIYOCOCOKARA & CO.	-0.06%	+3.10%	-9.16%	+1.74%	6.58B
TSURUHA HOLDINGS INC.	+2.02%	+0.88%	-16.14%	+4.92%	6.44B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	+0.70%	-4.66%	-51.60%	-35.18%	5.91B
YIFENG PHARMACY CHAIN CO., LTD.	-1.13%	+1.12%	+0.60%	-3.85%	4.61B
COSMOS PHARMACEUTICAL CORPORATION	+0.41%	-1.67%	-14.82%	-14.74%	3.21B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-0.77%	-2.42%	-2.78%	-20.91%	3.1B
CLICKS GROUP LIMITED	-6.97%	-9.76%	-42.31%	-11.24%	3.02B
Average	+0.39%	-2.04%	-19.47%	-7.43%	5.52B
Weighted average by Cap.	+0.87%	-1.82%	-22.10%	-5.80%

	2024	2025
Net sales	0.68 0.07 0.06 0.06 0.05 0.1 6.45 0.1 0.27 3.38 0.26 0.25 10.66	0.69 0.07 0.06 0.06 0.05 0.1 6.57 0.1 0.27 3.44 0.26 0.25 10.85
Net income	-17.4M -1.75M -1.57M -1.45M -1.31M -2.45M -166M -2.49M -6.89M -87.17M -6.58M -6.44M -275M	-26.19M -2.64M -2.36M -2.18M -1.97M -3.69M -250M -3.75M -10.37M -131M -9.9M -9.69M -414M
Net Debt	-2.77M -279K -249K -230K -209K -391K -26.51M -397K -1.1M -13.89M -1.05M -1.03M -43.79M	-27.01M -2.72M -2.43M -2.24M -2.03M -3.81M -258M -3.87M -10.69M -135M -10.21M -9.99M -427M